NICE Backs Pradaxa(R) (Dabigatran Etexilate) - The First Oral Anticoagulant In Over Fifty Years Part 2

Dr Sheuli Porkess, Head of Medical and Scientific Affairs at Boehringer Ingelheim, UK, comment: "As a innovative oral once morning after day anticoagulant, Pradaxa® clench the latent to complete up long-suffering thoroughness dispatch hip and knees swap surgery. We be massively thrilled that this close from NICE bring this a footfall closer - chiefly thus swiftly after European marketing authorisation contained by March 2008." Pradaxa® be a novel aim thrombin inhibitor next to a promptly start and neutralize of handling and a probable anticoagulation effect.8,9 It impede thrombus base by system of freeway and selectively inhibit thrombin, the final and acme enzyme in the coagulation fall that enable rendition of fibrinogen into fibrin.10,11 Final NICE guidance in support of National Health Service clinical custom is scheduled to be issue shortly. Pradaxa® be agreed for marketing in all EU partaker province by the EMEA in March 200812 and has already received bubbly recommendation from district Health Technology unit in Scotland (Scottish Medicines Consortium) and Denmark (IRF) in June 200813,14 and it has be unclaimed in Germany and the UK since April. Marketing sanction has also been granted in Canada.15 # Drug interactions for Pradaxa®: anticoagulants and platelet aggregation agents; amiodarone (reduce Pradaxa® dose to 150mg); caveat with imposing P-glycoprotein inhibitors (e.g. verapamil, clarithromycin or inducers, e.g. rifampicin, St John's wort) The direct of the mill recommended dosage of Pradaxa® is a positive oral dose of 220 mg given once daily.7 A particular medication of 110 mg (half-dose) is administered noticeably linking 1 and 4 hours consequent surgery, continuing with 2 capsule once daily thereafter for a utter of 10 days overall knee replacement patients and 28-35 days in total hip replacement patients.7 A second approved dosage of 150 mg taken in place of two capsules of 75 mg is recommended for specific patient populations, together with patients completed 75 years of age and those with clement renal impairment.7 Boehringer Ingelheim propagate to match up to the efficacy and sanctuary of Pradaxa® in a enumerate of thromboembolic virus stipulations through the blanket clinical experimentation list of items, RE-VOLUTION™, which involve over 38,000 patients maoist. Recent progress contain the announcement in January 2008 of the culmination of enrolment of 18,113 patients in RE-LY™, the largest lay a hand on control in atrial fibrillation outcome trial to date.